NewsVandana Singh
Pfizer
PFE · NYSE
$30.11+$0.67 (+2.28%)TodayMarket closed ·
Prev close $29.44
News sentiment
Tone of recent coverage
Social media sentiment, last 30 days
Average tone of posts mentioning PFE, from −1 (all negative) to +1 (all positive). Latest day: +0.00 across 22 mentions.
Latest news
- NewsMohd Haider
JD Vance Touts TrumpRx Drug Price Push, Trump Accounts as ‘Economic Nationalism’ Wins Ahead Of Midterms
- NewsEvette Mitkov
Pfizer Stock Hits 52-Week High: What's Going On?
- Press releaseBusiness Wire
Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026
- NewsAnanya Gairola
Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'
- NewsNeeraj Jain
A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally
- NewsMohd Haider
Pharma Lobby Sues Trump Administration Over Medicare Drug Pricing Rule, Calls It ‘Unlawful Overreach’ — ‘The Results Are Preordained’
- NewsVandana Singh
Pfizer Expands Breast Cancer Drug Reach with New FDA Nod for Metastatic Disease
- Press releaseBusiness Wire
Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer
- Press releasePRNewswire
Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026
- Press releaseBusiness Wire
Pfizer Declares Fourth-Quarter 2026 Dividend
- NewsVandana Singh
Florida Attorney General Sues Pfizer for 'Misleading' COVID-19 Vaccine Safety Claims
- NewsVandana Singh
Vaxcyte Stock Hits New 52-Week High - Here’s Why
- News
Pfizer Announces Its Two Phase 3 Studies Of LITFULO Demonstrate TRANQUILLO 2 and TRANQUILLO, LITFULO Enhance Facial, Total Body Repigmentation Compared To Placebo; Co. Plans To File Data to Regulatory Authorities Globally, Include FDA And European Medicines Agency
- Press releaseBusiness Wire
Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo
- NewsVandana Singh
Pfizer Says Eczema Drug Shows Significant Skin Clearance
- Press releaseBusiness Wire
Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study
- News
10 Health Care Stocks With Whale Alerts In Today’s Session
- NewsVandana Singh
Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 Antibody
- News
Full Transcript: Pfizer Q2 2026 Earnings Call
- Press releaseBusiness Wire
Pfizer Advances Today’s Cancer Care and Tomorrow's Potential Breakthroughs at ESMO
- Press releaseBusiness Wire
Pfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with Analysts
- NewsVandana Singh
Trump's Drug Price Achievements Questioned Following Separate Most Favored Nation Contract Disclosures with Lilly, Pfizer
- NewsVandana Singh
Merck Advances European Regulatory Approval For Keytruda Combination In Bladder Cancer
- Press releaseBusiness Wire
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
- Press releaseGlobe Newswire
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- NewsRadhika Anilkumar Nadig
Trump's Surgeon General Pick Has Tobacco, Cola Stocks In Portfolio Even as Robert Kennedy Jr. Wages War On Sugary Drinks, Processed Food
- Press releaseBusiness Wire
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
- NewsVandana Singh
Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion
- NewsNamrata Sen
Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President
- NewsAvi Kapoor
Take Two Interactive, Nvidia, Cheniere Energy And A Health Care Stock: CNBC’s ‘Final Trades’
- News
QUICK SPARK: FDA Approves Updated COVID Vaccines From Moderna, Pfizer, Novavax
- NewsAvi Kapoor
Dow Jumps Over 900 Points As Crude Oil Falls: Investor Sentiment Improves Further, Fear Index Moves To ‘Greed’ Zone
- NewsVandana Singh
Pfizer Says Monthly GLP-1 Candidate Could Rival Tirzepatide on Weight Loss
- NewsAvi Kapoor
Dow Jumps Over 700 Points; Pfizer Posts Upbeat Q2 Earnings
- NewsEva Mathew
Stock Market Today: S&P 500, Dow and Nasdaq Futures Gain as Scott Bessent Says Hormuz Deal Could Come Soon— Caterpiller, Palantir in Focus (UPDATED)
- Press releasePRNewswire
NYSE Content Update: ADI to Make NYSE Trading Debut After Spin-Off
- News
Pfizer Q2 Adj. EPS $0.77 Beats $0.69 Estimate, Sales $15.034B Beat $14.412B Estimate
- Press releaseBusiness Wire
Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance
- Press releaseBusiness Wire
Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts
- Press releaseBusiness Wire
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
- Press releaseBusiness Wire
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
- Press releaseBusiness Wire
Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance
- NewsAvi Kapoor
How To Earn $500 A Month From Pfizer Stock Ahead Of Q1 Earnings
- Press releaseBusiness Wire
Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.